ADAPY · Adaptimmune Therapeutics PLC
$0.03
+0.00 (+11.30%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2025
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Market Cap
$44.53M
Shares
1.59B
Volume · Oct 20
80.26K
Avg daily vol (3M)
144.54K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.03
52W close$0.00–0.07
Avg vol 30d153K
Short int1.2M · 0.1% float · 2.1d
Short vol0%
Last earningsMay 13, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$65.08M
Trailing 12 months
Net income (TTM)
−$169.76M
Trailing 12 months
Revenue growth YoY
-89.3%
Year over year
Operating margin
-252.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-512.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$386,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.6%
Year over year · more shares
Price change (1Y)
-85.4%
Trailing year
Short interest
0.1%
Latest settlement · 2.1 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+24%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
44%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+43%
trailing
6-month return
+3150%
trailing
YTD return
+25%
this year
Relative strength
+3142%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Distributing
-91% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -0.2% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+195%
Y/Y
EPS growth
+44%
Y/Y
Free cash flow
$-74.1M
Balance sheet
$36.9M
net cash
Quant / Vol
risk profile
Volatility
1514%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
26.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+24%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
44%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Distributing
-91% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -0.2% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 44%
Range high $0
vs 200-day avg +35%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADAPY
this stock
Adaptimmune Therapeutics PLC
|
$44.53M | +25.0% | +195.3% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADAPY | +14.0% | +42.5% | +3150.0% | -14.5% | +25.0% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +15.2% | +43.1% | +3141.9% | -15.3% | +12.2% |